Safety of Cannabidiol Given to Subject With Methadone or Buprenorphine – Full Text View
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05076370 |
|
Recruitment Status :
Recruiting First Posted : October 13, 2021 Last Update Posted : October 13, 2021 |
Sponsor:
Information provided by (Responsible Party):
Joao De Aquino, Yale University
Brief Summary:
The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an adjunctive treatment for comorbid opioid use disorder (OUD) and chronic pain. This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of CBD on measures of pain and opioid craving in outpatients with OUD receiving medication-assisted treatment (MAT) with methadone or buprenorphine.
|
Addiction |
Drug: CBD Day 1 Drug: CBD Day 2 Drug: CBD Day 3 |
Early Phase 1 |
An initial safety pilot phase will recruit six participants: three receiving treatment with methadone and three receiving treatment with buprenorphine. If the results of the pilot study support the safety of CBD administration in this clinical sample, the general study will recruit 48 participants with comorbid OUD and chronic pain, for a total of 24 completers – 12 subjects (6 men and 6 women) receiving methadone and 12 subjects (6 men and 6 women) receiving buprenorphine. Both sub-studies will enroll participants who do not currently require an inpatient hospitalization.
|
Study Type : |
Interventional (Clinical Trial) |
| Estimated
Enrollment : |
6 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Crossover Assignment |
| Intervention Model Description: | Initial safety pilot phase of 6 participants,(3 methadone and 3 on Buprenorphine) The general study is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of CBD on measures of pain and opioid craving in outpatients with OUD receiving medication-assisted treatment (MAT) with methadone or buprenorphine. |
| Masking: | None (Open Label) |
| Primary Purpose: | Health Services Research |
| Official Title: | Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain |
| Actual Study Start Date : | June 30, 2021 |
| Estimated Primary Completion Date : | June 30, 2022 |
| Estimated Study Completion Date : | August 31, 2022 |
|
Active Comparator: CBD 400mg CBD 400mg
|
Drug: CBD Day 1 CBD 400mg
|
|
Active Comparator: CBD 800mg CBD 800mg
|
Drug: CBD Day 2 CBD 800mg
|
|
Active Comparator: CBD 1200mg CBD 1200mg
|
Drug: CBD Day 3 CBD 1200mg
|
- Pain Threshold [ Time Frame: 4 measurements per test day, 3 total test days ]
The Cold Pressor (CPT measures Pain threshold (in seconds). For this test, a cooler filled with cold water (32.9-34.7degrees F/0.5-1.5 degrees C) are used. Participants are instructed to immerse their hand into the water and report the first time they experience pain (pain threshold). Lower scores indicate lower pain threshold. Minimum score is 0 seconds, and a maximum cut-off score of 300 seconds is used to prevent tissue damage.
- Pain Tolerance [ Time Frame: 4 measurements per test day, 3 total test days ]
The Cold Pressor Test (CPT) measures pain threshold and pain tolerance (in seconds). For this test, a water cooler is filled with cold water (32.9-34.7ºF/0.5-1.5ºC) are used. To begin the CPT, Participants are then instructed to immerse their hand into the cold water bath and report when the pain becomes unbearable (pain tolerance). Lower scores indicate lower pain tolerance. Minimum score is 0 seconds, and a maximum cut-off score of 300 seconds is used to prevent tissue damage.
- Pain Threshold [ Time Frame: 4 measurements per test day, 3 total test days ]
The QST is a reliable, dynamic, and computerized method of quantifying distinct mechanisms of the pain experience
- Pain Tolerance [ Time Frame: 4 Measurements per test day, 3 total days. ]
The QST is a reliable, dynamic, and computerized method of quantifying distinct mechanisms of the pain experience
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males and females, Veterans and non-Veterans, aged between 18 and 70 years old.
- Diagnosed with OUD and currently enrolled in methadone or buprenorphine maintenance treatment.
- Having chronic pain, uniformly operationalized as grade II (high-intensity) non- cancer pain for ≥ 6 months 49.
- Capable of providing informed consent in English.
- Compliant in opioid maintenance treatment and on a stable dose for four weeks or longer.
- Not meeting DSM-5 criteria for substance use disorders other than OUD or tobacco use disorder within the last 12 months.
- No current medical problems deemed contraindicated for participation by principal investigator.
- For women, not pregnant as determined by pregnancy screening; not breast-feeding; using acceptable birth control methods. Acceptable contraception for females includes oral contraceptives, contraceptive depot injections, contraceptive subdermal implants, intrauterine devices, or surgical contraception methods. Acceptable contraception for males includes condoms or surgical contraception methods.
Exclusion Criteria:
- Other current major psychiatric disorders deemed clinically unstable by the principal investigator, such as severe depression and/or active suicidal ideation.
- Having experienced major psychosocial stressors recently (≤ 6 weeks before enrollment), at the discretion of the principal investigator.
- Methadone dose under 60mg or over 100mg
- Buprenorphine over 24mg.
- Having received inpatient psychiatric treatment recently (≤ 60 days before enrollment).
- Candidates receiving products containing either THC or CBD will be excluded.
- Current use regular use other prescription opioids, gabapentinoids (pregabalin, gabapentin), antidepressants (SSRIs, SNRIs, TCAs), benzodiazepines, platelet inhibitors (e.g., clopidogrel, apixaban, ticagrelor), or NSAIDs.
- Current weight of less of 60 kg.
- Allergy to sesame seed oil, which is an ingredient of the CBD formulation used.
- Serious medical or neurological illness or treatment for a medical disorder that could interfere with study participation as determined by principal investigator.
- Participants who have elevation of liver enzymes (ALT and/or AST) 2x above the normal limit or higher.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05076370
| Veteran Affairs Hospital | |
| West Haven, Connecticut, United States, 06516 | |
| Contact: Brendan Sullivan 203-932-5711 ext 3350 brendan.sullivan@va.gov | |
| Principal Investigator: Mehmet Sofuoglu, M.D., Ph.D. | |
Yale University
| Principal Investigator: | Joao De Aquino, M.D. | Yale University |
| Responsible Party: | Joao De Aquino, Principal Investigator, Yale University |
| ClinicalTrials.gov Identifier: |
NCT05076370 |
| Other Study ID Numbers: |
2000029286 |
| First Posted: | October 13, 2021
Key Record Dates |
| Last Update Posted: | October 13, 2021 |
| Last Verified: | October 2021 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Behavior, Addictive Compulsive Behavior Impulsive Behavior |
Comments are closed.